Netherlands - More stringent blood donor testing requirements
2015 Mapping exercise

Colour key	
	Minimum requirements as set out in the 2004/33/EC Directive
	More stringent testing - legally binding on national level
	More stringent testing - recommended on national level
	Not legally binding and not recommended on national level

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfection or plasma for fractionantion)	Circumstances for application/ donor profile	Regional differences	Further comments
Basic testing								
Blood group testing	AB0 typing	YES	NO	N/A	both	universal screening	NO	
	RhD typing	YES	NO	N/A	both	universal screening	NO	
	Other, please specify (Kell etc.)	NO	YES	Health Council of the Netherlands [http://www.gezondheidsraad.nl/sites/default/files/200904.pdf; ISBN 978-90-5549-753-9], CBO [http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf], and Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	whole blood/ blood components for transfusion	selective screening	NO	The large majority of the Dutch donor population is typed for the rhesus phenotype (C, c, D, E and e) and the K-type (K negative or K positive); for patients with clinically relevant alloantibodies and for certain patient categories, specific requirements are set with regard to the transfusion of typed red blood cells
HLA testing	HLA/ Technique not specified	NO	YES	CBO [http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf], and Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	whole blood/ blood components for transfusion	selective screening	NO	In order to make HLA/HPA matched platelet transfusions possible, HLA/HPA testing of selected donors is performed using PCR based and solid-phase based techniques
	HLA Ab							
	HLA Ag							
	HLA gene							
	Other technique							
Disease testing								
VIRAL								
HIV 1 and HIV 2	Anti-HIV 1	YES	NO	N/A	both	universal screening	NO	A multiplex real-time PCR test is used to simultaneously screen donated blood for HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA
	Anti-HIV 2	YES	NO	N/A	both	universal screening		
	HIV 1p24							
	HIV NAT pool	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	both	universal screening		
	HIV NAT ID							
	Other technique							
Hepatitis B virus	HBsAg	YES	NO	N/A	both	universal screening	NO	A multiplex real-time PCR test is used to simultaneously screen donated blood for HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA; all donations of blood and blood components are tested for presence of HBsAg, HBV DNA and anti-HBc; anti-HBs levels are determined for anti-HBc repeatedly reactive donations (donations showing anti-HBs levels <200 mIU/mL are then not released)
	Anti-HBc	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	both	universal screening		
	Anti-HBs	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	both	anti-HBc positive donors only are tested for the presence of anti-HBs		
	HBV NAT pool	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	both	universal screening		
	HBV NAT ID							
	Other technique							
Hepatitis C virus	Anti-HCV	YES	NO	N/A	both	universal screening	NO	A multiplex real-time PCR test is used to simultaneously screen donated blood for HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA
	HCV NAT pool	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	both	universal screening		
	HCV NAT ID							
	Other technique							
Hepatitis E virus								In order to meet the requirements of the European Pharmacopeia,

Netherlands - More stringent blood donor testing requirements
2015 Mapping exercise

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfection or plasma for fractionantion)	Circumstances for application/ donor profile	Regional differences	Further comments
								EMA guidelines, Plasma Master File and European Directives, plasma for the manufacture of PDMPs may be routinely tested by NAT for the presence of HEV RNA (HEV RNA positive plasma donations are then not released)
HTLV-1	HTLV-1/ technique						NO	
HTLV-2	HTLV-2/ technique not specified						NO	
	Anti-HTLV-2	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	both	new donors only		
	HTLV-2 NAT pool							
	HTLV-2 NAT ID							
	Other technique							
Ebola Virus								
Chikungunya virus								CHIKV detection by NAT is ready for implementation to practice in certain epidemiological situations
Cytomegalovirus	CMV/ technique not specified						NO	Anti-CMV IgG negative tested blood components are provided at the request of treating experts for intra-uterine use or to administer to extremely premature babies
	Anti-CMV	NO	YES	CBO [http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf]	whole blood/ blood components for transfusion	on demand testing		
	CMV NAT pool							
	CMV NAT ID							
	Other technique							
West Nile Virus*								WNV detection by NAT is ready for implementation to practice in certain epidemiological situations
Dengue Virus								DENV detection by NAT is ready for implementation to practice in certain epidemiological situations
Epstein-Barr virus								
Human Parvovirus B19	HPVB19/ technique not specified	NO	YES	Health Council of the Netherlands [http://www.gezondheidsraad.nl/sites/default/files/0207n.pdf; ISBN 90-5549-432-1], and CBO [http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf]	whole blood/ blood components for transfusion	selective screening	NO	Parvo B19-virus safe cellular blood products are administered to selected groups of patients; donors with detectable IgG antibodies to B19 in two separate blood samples, one taken at least six months after the other, are considered to be B19 safe; in order to meet the requirements of the European Pharmacopeia, EMA guidelines, Plasma Master File and European Directives, plasma for the manufacture of PDMPs may be routinely tested by NAT for the presence of Parvo B19-virus DNA (B19 DNA positive plasma donations are then not released)
	HPVB19 NAT pool							
	HPVB19 NAT ID							
	Other technique							
Herpes simplex								
Nonspecific viral								

Netherlands - More stringent blood donor testing requirements
2015 Mapping exercise

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfection or plasma for fractionantion)	Circumstances for application/ donor profile	Regional differences	Further comments
Hepatitis A virus								In order to meet the requirements of the European Pharmacopeia, EMA guidelines, Plasma Master File and European Directives, plasma for the manufacture of PDMPs may be routinely tested by NAT for the presence of HAV RNA (HAV RNA positive plasma donations are then not released)
PARASITIC								
Malaria	Technique not specified						NO	Malaria antibody testing is performed to determine acceptance or rejection of blood donor candidates who give a history of malaria and/or have lived in a malaria area for a continuous period of 6 months or more
	Microscopy							
	Plasmodium sp . Ab	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	whole blood/ blood components for transfusion	selective screening		
	Plasmodium sp . Ag							
	Plasmodium sp. Ag - rapid test							
	Plasmodium sp. NAT pool							
	Plasmodium sp. NAT ID							
	Other technique							
Trypanosomiasis								
Babesiosis								
Leishmaniasis								
Toxoplasmosis								
Other pathogen,								
BACTERIAL								
Treponema pallidum (Syphilis)	Technique not specified						NO	
	Microscopy							
	Anti-*T. pallidum*	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public	both	universal screening		
	T. pallidum NAT pool							
	T. pallidum NAT ID							
	Culture							
	Other technique							
Neisseria								
Brucellosis								
Tuberculosis								
Q-fever								*C. burnetii* detection by NAT is ready for implementation to practice in certain epidemiological situations
Bacterial contamination	Automated microbial growth and detection technology	NO	YES	Medical Advisory Council of Sanquin Blood Supply Foundation [guidance document not available in the public domain]	all platelet products	platelet products only	NO	Products are released on a negative-to-date basis
FUNGI								
specify pathogen								

* For West Nile Virus NAT ID, see 2004/33/EC as amended by 2014/110/EU with a deadline for transposition into national law of December 31, 2015